Welcome to Markets Desk, your midday read on what's moving markets and why.
CoreWeave is joining the Nasdaq-one hundred effective June twenty-second, before the open. The addition signals institutional validation for the AI infrastructure company, which went public earlier this year. Index inclusion typically triggers forced buying from passive funds, so expect a technical bid in the days ahead, though valuation remains a live debate.
Shifting to biotech, Grail's Galleri multi-cancer blood test is edging closer to real-world adoption, but investors should pump the brakes. The test, which screens for more than fifty cancer types, missed a key primary endpoint in its landmark trial. That's not a death blow, but it does complicate the regulatory and commercial path meaningfully.
And in the AI space, Anthropic has filed a confidential S-one with the SEC at a reported valuation of nearly one trillion dollars. That puts it in rare company for a private company seeking public markets. The filing is confidential, meaning no prospectus yet, but it signals the company is preparing for a listing window and watching rate conditions closely.
That's the tape. Markets Desk, signing off the floor.
